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Summary
Objective: To characterize the mechanism of glycopeptide resistance and to determine the
genetic relatedness among strains by pulsed-field gel electrophoresis (PFGE) in vancomycin-
resistant Enterococcus faecium from Argentina.
Materials and methods: A total of 189 vancomycin-resistant single-patient isolates of Enter-
ococcus faecium recovered between January 1997 and December 2000 from 30 hospitals in
Argentina were studied. Minimum inhibitory concentrations were determined by the agar dilution
method and van genes were detected by PCR. PFGE was used for molecular typing.
Results: All isolates except three (vanB) were of genotype vanA. For 189 vancomycin-resistant
Enterococcus faecium, SmaI-PFGE indicated 35 clonal types. Most of the isolates (56%) belonged
to the same clonal type 1, which was present in 19 hospitals and dominant in 17.
Conclusions: The emergence of vancomycin-resistant Enterococcus faecium in Argentina seems
to be related to the intra- and inter-hospital dissemination of an epidemic clone carrying the vanA
element.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.§ This study was presented in part at the 41st Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, Chicago, Illi-
nois, USA, December 16—19, 2001, Abstract No. 509.
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Enterococci as a cause of nosocomial infection have become
more prevalent over the last 20 years, both in the USA and in
Western European countries. Strains of enterococci have
acquired resistance to almost all antimicrobial agents,
including vancomycin.
Vancomycin-resistant Enterococcus (VRE) was first iso-
lated in the UK and France in 1986,1 and one year later,Published by Elsevier Ltd. All rights reserved.
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tant differences in the epidemiology of VRE in the USA and
Europe were observed. In the USA, the major factor con-
tributing to the dissemination of VRE was the excessive use of
glycopeptides and other antibiotics in the healthcare envir-
onment. In contrast, in Europe the emergence of VRE took
place outside hospitals. A large reservoir of transferable vanA
gene cluster was identified in animal husbandry and has been
associated with the use of avoparcin as a growth promoter in
animal feed.3—5
Nowadays, VRE are distributed worldwide. The incidence
of VRE infection in the USA has greatly increased over the
past 15 years. Within 10 years VRE representedmore than 25%
of enterococci associated with bloodstream infections in
hospitalized patients in the USA.6 In Latin America, VRE have
been reported in Brazil7 and Colombia.8 In Argentina, the first
reported VRE, an Enterococcus faecium isolate carrying the
vanA gene, was isolated in 1997 from a blood culture.9 After
that, many hospitals in our country implemented a survey of
stool or rectal swab cultures in order to detect VRE coloniza-
tion and to prevent and control nosocomial transmission.
Between January 1997 and December 2000, at the Anti-
microbial Division of the National Institute of Infectious
Diseases (INEI) ‘‘Dr. C.G. Malbra´n’’, we received a total of
189 vancomycin-resistant E. faecium from 30 hospitals.
Almost all Argentinean hospitals that had identified vanco-
mycin-resistant E. faecium up to December 2000 contributed
their isolates to this study. Themain objectives of the present
study were to characterize the mechanisms of glycopeptide
resistance and to evaluate the mode of dissemination of
vancomycin-resistant E. faecium isolates in Argentina.
Materials and methods
Clinical isolates
From January 1997 to December 2000, 189 vancomycin-
resistant E. faecium from 30 hospitals were received at
the INEI to confirm the genotype. Eleven enterococci
(5.8%) were recovered during 1997, 49 (25.9%) in 1998, 67
(35.5%) in 1999, and 62 (32.8%) in 2000. Isolates were iden-
tified in each hospital to the species level with conventional
biochemical tests as described by Carvalho et al.10 One
hundred and twenty-five (66.1%) isolates were collected from
20 hospitals in Buenos Aires City, 52 (27.5%) from six hospitals
in the Province of Buenos Aires, three (1.6%) from two
hospitals in the Province of Co´rdoba (700 km from Buenos
Aires City), seven (3.7%) from one hospital in the Province of
Chaco (970 km from Buenos Aires City), and two (1.1%) from
one hospital in the Province of Santa Fe (480 km from Buenos
Aires City). Names, locations, and the number of isolates
recovered from each hospital are listed in Table 1.
Vancomycin-resistant E. faecium strainswere isolated from
rectal swabs in 145 (76.7%), urine in 17 (9%), blood in nine
(4.8%), and from other sources in 18 (9.5%). Only the initial
isolate of each patient was included in the study. Most of the
strains were isolated in the intensive care units (ICU) (46.5%)
and general medicine wards (36%). One hundred and fifty-two
patients (80.4%)werecolonizedwithVRE, 28 (14.8%)exhibited
signs of clinical infection, and in nine (4.8%) cases an assess-
ment of the clinical significance was not possible.Antimicrobial susceptibility
Minimum inhibitory concentrations (MICs) to ampicillin (Bago´
Argentina), vancomycin (Lilly), teicoplanin (Aventis Pharma),
gentamicin (Schering—Plough), streptomycin (Rontag), tet-
racycline (Phoenix), chloramphenicol (Parke Davis), erythro-
mycin (Lilly), and ciprofloxacin (Roemmers Argentina) were
determined by the agar dilution procedure according to the
Clinical and Laboratory Standards Institute (CLSI, formerly
NCCLS) recommendations.11,12 Quality control strains used
were Staphylococcus aureus ATCC 29213, E. faecalis ATCC
29212, and E. faecalis ATCC 51299.
PCR amplification of glycopeptide resistance
genes
The presence of van genes was detected by PCR using specific
primers for vanA and vanB and conditions already
described.13 DNA template was prepared by the boiling
method. Reactions were performed with a Biometra thermal
cycler (Whatman Biometra GmbH, Go¨ttingen, Germany). The
PCR amplification products were analyzed in 1% agarose gel.
E. faecalis vanA Tx2403 and E. faecium vanA WHO-3 used as
positive controls, were kindly provided by Barbara Murray
(University of Texas at Houston, USA) and Fred Tenover (CDC,
Atlanta, GA, USA), respectively. Specific primers for the 16S
ribosomal RNA gene were used as controls of DNA extrac-
tion.14 Amplification of the intergenic vanS—vanH region was
performed using the specific primers, vanS-f (forward) and
vanH-r (reverse), as described by Brown et al.15 PCR-RFLP
was performed on vanSH amplicons, using HindIII and EcoRI
enzymes as recommended by themanufacturer (New England
Biolabs, Beverly, MA, USA).
PFGE typing
Isolates were grown overnight in brain—heart infusion broth.
Chromosomal DNA was prepared in agarose plugs and sub-
jected to endonuclease digestion with SmaI (New England
Biolabs, Beverly, MA, USA) as previously described.16 DNA
fragments were separated in 0.8% agarose using a CHEF-DRIII
apparatus (Bio-Rad Laboratories, Richmond, CA, USA), with
running conditions of 6 V/cm and pulses ranging from 5 to
35 seconds during 26 h at 7 8C. Lambda ladder (New England
Biolabs) was used as molecular size standard. Gels were
stained with 1 mg/mL ethidium bromide and photographed
under UV illumination. The similarity between isolates was
determined by visual comparison of isolate banding patterns.
The interpretation of the band patterns was carried out
according to previously published guidelines.17 Isolates were
defined as distinct strain types, or unrelated, if their PFGE
patterns differed by more than six bands. Types were named
using a consecutive Arabic number (e.g. type 1, 2, 3). Sub-
types were defined as strains that differed by 2—6 bands,
which were considered closely or possibly related, and were
named using a letter following the Arabic number (e.g.
subtype 1a, 1b, 1c). Those isolates whose restriction patterns
had the same number and size of bands were considered
genetically indistinguishable and were assigned to the same
strain type and subtype.
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Table 1 Origin and clonal type of 189 clinical isolates of vancomycin-resistant Enterococcus faecium from Argentina
Hospital a Cityb Type of
hospital
Resistance
gene
Total no. of
isolates
No. of isolates
by clonal type
PFGE type and subtypec
(No. of isolates)
AER BAC Community vanA 4 4 5 (4)
ANT BAC Community vanA 3 2 8a (2)
1 34 (1)
BAN BAC Community vanB 2 2 10 (2)
BAZ BAC Community vanA 3 3 1d (3)
CML BAP Community vanA 1 1 1l (1)
COS BAC Community vanA 18 13 1a (1); 1e (1); 1g (1);
1i (1); 1j (1); 1k (3); 1l (1);
1m (1); 1v (1); 1x (1); 1y (1)
vanA 2 3a (2)
1 8b (1)
vanA 1 11 (1)
vanA 1 32 (1)
DUR BAC Community vanA 20 8 1a (1); 1c (3); 1d (1);
1h (1); 1i (1); 1l (1)
vanA 5 4a (5)
vanA 3 2b (3)
vanA 2 15 (2)
vanA 1 30 (1)
vanA 1 31 (1)
EVI BAC Community vanA 18 17 1d (5); 1l (1); 1s (8);
1t (1); 1u (2)
vanA 1 27 (1)
FAV BAC Cardiology vanA 5 3 3a (3)
vanA 2 6a (2)
FER BAC Community vanA 18 14 1a (8); 1c (2); 1d (1);
1l (2); 1n (1)
vanA 1 2a (1)
vanA 1 11 (1)
vanA 1 12 (1)
vanA 1 26 (1)
FLE BAC Neurology vanA 2 2 1a (1); 1o (1)
GAR BAC Pediatrics vanA 1 1 33 (1)
HCC COR Community vanA 2 2 2c (1); 2d (1)
HIE BAP Obstetrics vanB 1 1 16 (1)
IPA SFE Community vanA 2 2 1a (2)
LAE BAC Community vanA 1 1 1b (1)
MIT BAC Community vanA 1 1 18 (1)
MUN BAC Infectious Disease vanA 9 8 1a (7); 1c (1)
vanA 1 24 (1)
PER CHA Community vanA 7 6 1a (1); 1p (1); 1q (3); 1r (1)
vanA 1 17 (1)
PIN BAC Community vanA 15 10 7a (6); 7b (2); 7c (1); 7d (1)
vanA 5 1a (2); 1c (2); 1f (1)
PIR BAC Community vanA 6 2 13 (2)
vanA 2 1a (1); 1b (1)
vanA 1 2e (1)
vanA 1 28 (1)
POS BAP Community vanA 11 2 3b (2)
vanA 2 9 (2)
vanA 2 14a (1); 14b (1)
vanA 1 19 (1)
vanA 1 20 (1)
vanA 1 21 (1)
vanA 1 22 (1)
vanA 1 23 (1)
QUE BAC Burn Center vanA 12 7 2a (7)
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Table 1 (Continued )
Hospital a Cityb Type of
hospital
Resistance
gene
Total no. of
isolates
No. of isolates
by clonal type
PFGE type and subtypec
(No. of isolates)
vanA 2 1a (2)
vanA 2 6b (2)
vanA 1 25 (1)
REI COR Community vanA 1 1 1a (1)
RIV BAC Community vanA 1 1 1a (1)
SMP BAP Community vanA 20 19 1a (14); 1d (1); 1e (3); 1g (1)
vanA 1 9 (1)
STJ BAC Community vanA 2 1 4 (1)
vanA 1 35 (1)
TOR BAC Community vanA 1 1 1a (1)
VLP BAP Community vanA 1 1 1m (1)
ZUB BAC Community vanA 1 1 29 (1)
a Hospital codes: AER, Htal. Aerona´utico; ANT, Sanatorio Anta´rtida; BAN, Policlı´nico Bancario; BAZ, Clı´nica Bazterrica; CML, Clı´nica Modelo
de Lanu´s; COS, Htal. Argerich; DUR, Htal. Durand; EVI, Htal. Evita; FAV, Fundacio´n Favaloro; FER, Htal. Fernandez; FLE, FLENI; GAR, Htal.
Garrahan; HCC, Htal. Co´rdoba; HIE, Htal. Tetamanti; IPA, Centro Me´dico IPAM; LAE, Laboratorio Especializado; MIT, Sanatorio Mitre; MUN,
Htal. Mun˜iz; PER, Htal. Perrando; PIN, Htal. Pin˜ero; PIR, Htal. Pirovano; POS, Htal. Posadas; QUE, Htal de Quemados; REI, Htal. Reina
Fabiola; RIV, Htal. Rivadavia; SMP, Htal. ‘‘San Martı´n’’ La Plata; STJ, Htal. Santojanni; TOR, Htal. Tornu´; VLP, Htal Vicente Lo´pez y Planes;
ZUB, Htal. Zubizarreta.
b City codes: BAC, Buenos Aires City; BAP, Province of Buenos Aires; COR, Province of Co´rdoba; SFE, Province of Santa Fe; CHA, Province of
Chaco.
c Isolates of clonal type 1 are shown in bold.Results and discussion
The emergence of VRE is a serious nosocomial problem with
important implications for hospital infection control.
Among the 189 isolates characterized in this study, 186
(98%) carried the vanA gene and only three the vanB gene
(Table 1). All vanA E. faecium showed high-level resistance
to vancomycin (MICs 32—512 mg/L) and teicoplanin (MICs
8—64 mg/L), which is characteristic of the vanA pheno-
type. The three isolates with the vanB phenotype showed
MICs of 16—32 mg/L for vancomycin and 0.12—1 mg/L for
teicoplanin as we described in a previous study.18 A pre-
dominance of E. faecium with the vanA genotype, as well
as the predominance of vanA over vanB observed in our
study have been previously described in VRE6,7,19,20 and
may be related to the less efficient mobilization of the
vanB complex.16 However, we cannot dismiss the possibi-
lity that the ratio between vanA and vanB genes could be
biased by the detection methods used in the primary
laboratories.Table 2 Antibiotic susceptibilities among 189 vancomycin-resist
Antibiotic MIC50 (mg/L) MIC90 (
Vancomycin 256 512
Teicoplanin 16 32
Ampicillin 64 128
Erythromycin >2048 >2048
Ciprofloxacin 64 >128
Chloramphenicol 4 8
Tetracycline 0.25 0.
Gentamicin 2048 >2048
Streptomycin >2048 >2048Enterococci are intrinsically resistant to many antimicro-
bial agents, including cephalosporins, low concentrations of
aminoglycosides, and trimethoprim—sulfamethoxazole.
Furthermore, the ability of enterococci to acquire resistance
to other agents like erythromycin, rifampin, chlorampheni-
col, ciprofloxacin, high concentrations of aminoglycosides,
and vancomycin is well recognized. Consequently, treatment
of VRE blood stream infections is a clinical challenge of great
concern. In our collection the percentage of resistance was,
as expected, high for vancomycin (100%), teicoplanin
(97.9%), ampicillin (98.4%), erythromycin (100%), ciproflox-
acin (98.9%), gentamicin (77.2%), and streptomycin (95.8%),
but relatively low for tetracycline (6.3%) and chlorampheni-
col (3.7%). Antimicrobial resistance profiles with MIC50 and
MIC90 are shown in Table 2. These results are similar to those
previously reported by Sader et al. in Brazil.19
The analysis of molecular typing demonstrated 35 PFGE
patterns among the 189 vancomycin-resistant E. faecium
isolates, as shown in Figure 1. One hundred and six isolates
(56%) belonged to the most frequent clone 1, which wasant Enterococcus faecium isolates from Argentina
mg/L) MIC range % Resistance
16—512 100
0.12—64 97.9
16—512 98.4
1—>2048 100
1—>128 98.9
0.5—64 3.7
5 0.03—128 6.3
2—>2048 77.2
16—>2048 95.8
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Figure 1 PFGE banding patterns of SmaI-digested chromosomal DNAs of vancomycin-resistant Enterococcus faecium strains. Lanes 1,
26, 27 and 40, lambda ladder; lane 2 and 28, epidemic clone 1a; lane 3, clone 2a; lane 4, clone 3a; lane 5, clone 4a; lane 6, clone 5; lane
7, clone 6a; lane 8, clone 7b; lane 9, clone 8a; lane 10, clone 9; lane 11, clone 10; lane 12, clone 12; lane 13, clone 14b; lane 14, clone
15; lane 15, clone 16; lane 16, clone 17; lane 17, clone 18; lane 18, clone 19; lane19, clone 20; lane 20, clone 21; lane 21, clone 22; lane
22, clone 23; lane 23, clone 24; lane 24, clone 25; lane 25, clone 26; lane 29, clone 13; lane 30, clone 28; lane 31, clone 29; lane 32,
clone 30; lane 33, clone 31; lane 34, clone 32; lane 35, clone 33; lane 36, clone 34; lane 37, clone 35; lane 38, clone 11; lane 39, clone
27. The sizes of the fragments (in Kb) are shown to the left. PFGE pattern of the epidemic vancomycin-resistant Enterococcus faecium
clone 1 is indicated by arrows.present in 19 of 30 hospitals (Table 1). The vancomycin-
resistant E. faecium clone 1 presented 24 subtypes (1a to
1y), out of which the most abundant was subtype 1a, shared
by 43/189 (22.8%) of the isolates. Clone 1 was present in all
the cities involved in the survey, representing 52% of the
isolates from Buenos Aires City, 73% from the Province of
Buenos Aires, and 75% from other cities. Clone 1 isolates were
resistant to all of the antibiotics tested with the exception of
tetracycline and chloramphenicol. Clone 2 was represented
by 14 isolates (7.4%) and was detected in four hospitals from
Buenos Aires City (DUR, FER, PIR, and QUE) and one from
Co´rdoba (HCC). Seven isolates representing clone 3 were
found in three hospitals, two from Buenos Aires City (COS
and FAV) and one from the Province of Buenos Aires (POS). Six
isolates of clone 4 were detected in two hospitals from
Buenos Aires City (DUR and STJ). Thus, most of the isolates
(70.4%) belonged to one of these four major clonal types. The
remaining 56 isolates (29.6%) were highly diverse, belonging
to 31 clonal types. Dominant clones distinct from clone 1
were detected in some hospitals. For example, in hospital
QUE, 7/12 isolates were of clonal type 2, in hospital AER 4/4
isolates were of clonal type 5, and in hospital FAV 3/3 were of
clonal type 3. In contrast, in some hospitals, high genetic
diversity was observed. In hospital POS, there were eight
clonal types among the 11 vancomycin-resistant E. faecium
isolates.
The presence of a dominant vancomycin-resistant E. fae-
cium clone (clone 1) in 17 of 30 hospitals shows that their
spread has occurred not only within individual hospitals but
also between hospitals of various geographic locations. Other
studies have documented the spread of vancomycin-resistantE. faecium19,21—23 and E. faecalis24—26 clones among hospi-
tals. In the present study, molecular typing results indicate
the clonal dissemination of vancomycin-resistant E. faecium
clone 1 in different wards of the same hospital, in different
hospitals, and in different cities. The absence of an ongoing
alert system for patients infected or colonized with vanco-
mycin-resistant enterococci upon hospital readmission in our
country may have contributed to this dissemination.
In some hospitals we observed a high number of clone 1
subtypes. In hospital COS there were 11 subtypes of the clone
1 and in hospital DUR six subtypes. The number of subtypes of
a particular clone may reflect the evolution of the clone in a
region and its relative age. Mutations, chromosomal rearran-
gements, as well as loss and acquisition of plasmids, trans-
posons, or insertion sequences could be responsible for
observed changes in PFGE profiles, resulting in different
clonal subtypes. Probably, an epidemic clone that has per-
sisted for a long time in a hospital subjected to an intensive
selective pressure had a higher chance of incorporating more
rearrangements in its genetic background than a non-epi-
demic clone.
Transposon Tn1546 was the first element described to
carry the vanA cluster.27 Tn1546 is highly heterogeneous,
because of the occurrence of deletions, insertions, and point
mutations.16,28 Although these events originated different
vanA elements, they could derive from a unique ancestral
Tn1546.29 De Lencastre et al. reported that the occurrence of
IS1251 is indicative of the presence of a larger transposon
(26 kb) named Tn5482.16 The insertion sequence IS1251was
found in the intergenic vanS—vanH region, mainly in isolates
from the USA.16,28 We selected one representative isolate
74 A.C. Corso et al.from each of the 33 vanA clonal types identified in this study,
and determined the presence of IS1251 by PCR of the inter-
genic region vanS—vanH. All 33 isolates carrying the vanA gene
yielded an 1871 bp amplimer when vanS-f and vanH-r primers
were used, suggesting the presence of an IS1251-like element.
The analysis of the 1871 bp amplimer by endonuclease diges-
tion with HindIII and EcoRI resulted in the same RFLP profile as
expected from the reported sequence (Genbank accession
numbers: Tn1546, M97297 and IS1251, L34675) (data not
shown). These results indicate the presence of IS1251 in the
intergenic region vanS—vanH and suggest the possible hori-
zontal dissemination of vanA through Tn5482. Recently we
described the transfer of the vanA element by conjugation
from highly resistant E. gallinarum isolates, carrying Tn5482,
to vancomycin-susceptible E. faecium.30
The most common clinical impact of VRE is intestinal
colonization, which may persist for long periods.31 Colonized
individuals are potential reservoirs for transmission of VRE
and should be identified and included in infection control
interventions, because they constitute a major route of
exposure.32 Transmission is mediated by factors such as
patient characteristics, antimicrobial use, and the preva-
lence of VRE within the hospital.20 A large number of clinical
studies have described the association of VRE colonization
or infection with the use of vancomycin, antibiotics with
activity against anaerobes, and extended-spectrum cepha-
losporins.20,31,33 Recent reports of three vancomycin-
resistant S. aureus34,35 and the already demonstrated hor-
izontal transfer of the vanA gene from vancomycin-resistant
E. faecalis to Staphylococcus aureus, underscores the impor-
tance of understanding VRE epidemiology.36
The emergence of predominant clonal types among multi-
ple strains in several institutions of the survey, may suggest
that some strains contain bacterial factors that enhance their
spread within hospitals. Recently, Shankar et al. and Willems
et al. have identified the esp gene encoding a surface protein
associated with virulence for E. faecalis37 and E. faecium,38
residing on a pathogenicity island.37,39 Several authors have
reported that the esp gene is not associated with vancomycin
resistance.40,41 On the other hand, Harrington et al. support
the hypothesis that in a clinical setting in which vancomycin-
resistant E. faecium is endemic, the combination of vanco-
mycin resistance and the esp gene could lead to dissemination
of particular clones. Recently, Willems et al. have identified a
genetic lineage of E. faecium, named complex-17, associated
with hospital outbreaks in five continents, representing the
first globally dispersed nosocomial clonal lineage.42 The sub-
sequent acquisition of vanA or vanB genes for the hospital-
adapted complex-17 resulted in vancomycin-resistant E. fae-
ciumwith pandemic potential. In thisway, it is probable that in
Argentina a particular E. faecium clone has been selected and
has adapted well to the hospital environment with the ability
to spread. Although the presence of the esp gene was not
assessed in the present study,wecannotdismiss the role of this
factor in the spread of dominant clones. Further studies are
necessary in order to investigate the presence of esp or other
genes belonging to pathogenicity islands. Moreover, additional
studies on the relation between the epidemic clone 1 and
complex-17 lineage would be valuable in elucidating the
epidemicity of this clone.
In summary, our results strongly suggest that intra- and
inter-hospital spread of an epidemic vancomycin-resistant E.faecium clone carrying the vanA element seems to be the
main mechanism of vancomycin-resistance dissemination in
Argentina.
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